Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib and Capecitabine in HER2+ Breast Cancer with Brain Metastases
NCT00967031Phase 2Completed
- Sponsor
- Unicancer
- Start
- Apr 2009
- Primary completion
- Feb 2012
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib and capecitabine in breast cancer and brain metastasis (BM), sponsored by Unicancer. Primary endpoint: Objective response rate. Started Apr 2009; status: completed.
02
Drugs
lapatinibcapecitabine
03
Conditions
breast cancerbrain metastasis (BM)
Beyond the preview
Go deeper on NCT00967031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00967031.